{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-000574","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.662860+00:00","generated_at":"2026-05-15T08:23:35.453226+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance","bullets":["Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.","Net proceeds of $10.03M to be used for working capital, corporate purposes, and repayment of bridge debt.","Common warrants exercisable at $3.20 for 5.5 years; potential additional proceeds of $20.4M if fully cash-exercised.","Proceeds push stockholders' equity above $2.5M threshold; company awaiting Nasdaq confirmation of compliance.","H.C. Wainwright acted as placement agent, receiving 8% cash fee plus warrants for 255,073 shares at $4.3125."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-000574","json":"https://secwatch.observer/filing/0001640334-26-000574.json","markdown":"https://secwatch.observer/filing/0001640334-26-000574.md","text":"https://secwatch.observer/filing/0001640334-26-000574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/0001640334-26-000574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:35.453226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30a773793f4788ba27e0717a0e686a738631fca3","claim":"ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/0001640334-26-000574-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$10,996,902.70"},{"label":"Effective","value":"2026-03-27"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}